ATTR-CM Now Approved

TTR letters explode outward from a heart

AMVUTTRA® DELIVERS

RAPID

KNOCKDOWN

As the first and only silencer for ATTR-CM, AMVUTTRA suppresses TTR production at the source. 1-4 

Serum TTR first measured at 6 weeks in HELIOS-B, a double-blind, placebo-controlled trial in adult patients with ATTR-CM evaluating AMVUTTRA q3m vs placebo. Patients receiving AMVUTTRA demonstrated 87% (95% CI: 84%–88%) median trough reduction at 30 months compared to baseline.4,5

NEJM article: Vutrisiran in Patients With ATTR‑CM

ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; NEJM=New England Journal of Medicine; q3m=every 3 months; TTR=transthyretin.

Get your patients started with AMVUTTRA   Explore AMVUTTRA for hATTR-PN  

Helpful resources

Download some helpful resources for AMVUTTRA.

Get resources

Find a treatment center

Locate a treatment center close to your patients.

View the directory

Stay informed

Receive helpful information for you and your patients.

Sign up

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References on Splash Page

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Tomasoni et al. Front Cardiovasc Med. 2023;10:1154594.
  3. Williams et al. J Cardiothorac Vasc Anesth. 2024;38(7):1457-1459.
  4. Fontana et al. N Engl J Med. 2025;392(1):33-44.
  5. Data on file. Alnylam Pharmaceuticals, Inc.